TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED

Taigen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs. The Company operates through two segments. The New Drug Research and Development and Drug Sales segment is mainly engaged in the research, development, manufacturing and sales of various new drugs and cell preparations. The Other segment provides medical technology consulting services. The Company's main products are Nemonoxacin and TG-100. Nemonoxacin is mainly used for nosocomial pneumonia infections, diabetic foot infections, urinary tract infections and complicated skin infections. TG-100 is mainly used for type A, type B influenza and avian influenza. Employees - Sector Pharmaceuticals